Literature DB >> 17935223

Transfer of suppressor of cytokine signaling 3 by an oncolytic adenovirus induces potential antitumor activities in hepatocellular carcinoma.

Qiang Cui1, Wei Jiang, Yingxin Wang, Chen Lv, Jingjing Luo, Wei Zhang, Fang Lin, Yuexiang Yin, Rong Cai, Ping Wei, Cheng Qian.   

Abstract

UNLABELLED: The constitutive activation of signal transducer and activator of transcription 3 (STAT3) participates in carcinogenesis through up-regulation of genes encoding apoptosis inhibitors and cell cycle regulators, such as Bcl-xL, cyclins D1 and D2, and c-myc. Suppressor of cytokine signaling 3 (SOCS3) is one of the negative regulators of cytokine signaling and is frequently silenced in diverse cancers. In this study, we explored whether restoration of SOCS3 by oncolytic adenoviral vectors could inhibit the constitutive activation of the Janus kinase/STAT pathway and suppress tumor growth. Our data showed that SOCS3 was down-expressed in all liver tumor cell lines. The incorporation of SOCS3 or SOCS3 fused with cell-penetrating peptides (cpp-SOCS3) did not alter adenoviral replication selectively in liver tumor cells. The infection of cells with adenovirus CN305 (AdCN305)-SOCS3 and AdCN305-cpp-SOCS3 resulted in dramatic cytotoxicity in liver tumor cells. However, no cytotoxic effect was observed in normal cells infected with these vectors. Infection of liver tumor cells with AdCN305-SOCS3 and AdCN305-cpp-SOCS3 resulted in nearly complete inhibition of STAT3 phosphorylation and down-regulation of cyclin D1 and Bcl-xL. Treatment of the established tumor by AdCN305-SOCS3 and AdCN305-cpp-SOCS3 caused significant suppression of tumor growth. The suppression of tumor growth was due to the inhibition of STAT3 phosphorylation and induction of tumor cell death.
CONCLUSION: This study suggests that transfer of SOCS3 by an oncolytic adenovirus represents a potent approach for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17935223     DOI: 10.1002/hep.21951

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  15 in total

Review 1.  SOCS3 revisited: a broad regulator of disease, now ready for therapeutic use?

Authors:  R Mahony; S Ahmed; C Diskin; N J Stevenson
Journal:  Cell Mol Life Sci       Date:  2016-05-02       Impact factor: 9.261

2.  Hepatoprotective versus oncogenic functions of STAT3 in liver tumorigenesis.

Authors:  Hua Wang; Fouad Lafdil; Lei Wang; Ogyi Park; Shi Yin; Junyang Niu; Andrew M Miller; Zhaoli Sun; Bin Gao
Journal:  Am J Pathol       Date:  2011-06-02       Impact factor: 4.307

3.  Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner.

Authors:  Run-Xuan Shao; Leiliang Zhang; Lee F Peng; Eileen Sun; Woo Jin Chung; Jae Yong Jang; Wei-Lun Tsai; Guibenson Hyppolite; Raymond T Chung
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

4.  Targeting eradication of chronic myeloid leukemia using chimeric oncolytic adenovirus to drive IL-24 expression.

Authors:  Xubin Wei; Li Liu; Gang Wang; Wei Li; Ke Xu; Xupang Hu; Cheng Qian; Jimin Shao
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

5.  Adenoviral gene therapy in hepatocellular carcinoma: a review.

Authors:  Iván Lyra-González; Laura Esther Flores-Fong; Ignacio González-García; David Medina-Preciado; Juan Armendáriz-Borunda
Journal:  Hepatol Int       Date:  2012-04-25       Impact factor: 6.047

6.  Mechanisms of STAT3 activation in the liver of FXR knockout mice.

Authors:  Guodong Li; Yan Zhu; Ossama Tawfik; Bo Kong; Jessica A Williams; Le Zhan; Karen M Kassel; James P Luyendyk; Li Wang; Grace L Guo
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-03       Impact factor: 4.052

Review 7.  Host restriction factors for hepatitis C virus.

Authors:  Li-Ya Zhou; Lei-Liang Zhang
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

Review 8.  The biology and mechanism of action of suppressor of cytokine signaling 3.

Authors:  Jeffrey J Babon; Nicos A Nicola
Journal:  Growth Factors       Date:  2012-05-11       Impact factor: 2.511

Review 9.  Armed replicating adenoviruses for cancer virotherapy.

Authors:  J J Cody; J T Douglas
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

10.  Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model.

Authors:  Zhi Yang; Qianzhen Zhang; Ke Xu; Juanjuan Shan; Junjie Shen; Limei Liu; Yanmin Xu; Feng Xia; Ping Bie; Xia Zhang; Youhong Cui; Xiu-Wu Bian; Cheng Qian
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.